Objective: To investigate the improvement of health-related quality of life during stable stage of chronic obstructive pulmonary disease(COPD) with salmeterol/fluticasone therapy using COPD assessment test(CAT). Methods: 125 subjects with moderate-to-severe COPD treated with a combination of tiotropium bromide and salmeterol/fluticasone(observed group, n=78), or Salmeterol/fluticasone alone(control group, n=47) were enrolled into this clinical trial and were observed for six months. All patients were documented their information after inclusion. Health-related Quality of life was measured by CAT and lung function test was done at baseline, third month and sixth month. The events of acute exacerbation were also recorded. Results: No significant differences existed between the two groups at baseline. After 3 month and 6 month the average improvements(lower CAT scores and higher FEV1%) were significant in both observed group and control group(P<0.05), and there had been a greater improvement in observed group. There were good association between CAT score and FEV1%(-0.58 to -0.79). In patients with acute exacerbation more than once during the six month were associated with higher CAT scores(P<0.05). Conclusions: In patients with stable COPD, compared with therapy with salmeterol/fluticasone alone,tiotropium bromide combined with salmeterol/fluticasone is associated with lower CAT score, higher quality of life and fewer exacerbations, under such a situation where CAT is a reliable for assessing health-related quality of life of stable COPD patient.
 JONES P W,HARDING G,BERRY P,et al.Development and first validation of the COPD Assessment Test[J].Eur Respir J,2009, 34(3):648-654.
 PAUWELS R A,BUIST A S,MA P,et al.Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease:National Heart,Lung,and Blood Institute and World Health Organization Global Initiative for Chronic Obstructive Lung Disease(GOLD):executive summary[J].Respir Care,2001,46(8):798-825.
 .Standardization of spirometry,1994 update. american thoracic society[J].Am J Respir Crit Care Med,1995,152(3):1107-1136.
 ZHONG N S,WANG C H,YAO W Z,et al.Prevalence of chronic obstructive pulmonary disease in China:a large,population-based survey[J].Am J Respir Crit Care Med,2007,176(8):753-760.
 AARON S D,VANDEMHEEN K L,FERGUSSON D,et al.Tiotropium in combination with placebo,salmeterol,or fluticasone-salmeterol for treatment of chronic obstructive pulmonary disease:a randomized trial[J].Ann Intern Med,2007,146(8):545-555.
 JUNG K S,PARK H Y,PARK S Y,et al.Comparison of tiotropium plus fluticasone propionate/salmeterol with tiotropium in COPD:A randomized controlled study[J].Respir Med,2012, 106(3):382-389.
 HANANIA N A,CRATER G D,MORRIS A N,et al.Benefits of adding fluticasone propionate/salmeterol to tiotropium in moderate to severe COPD[J].Respir Med,2012, 106(1):91-101.
 VOGELMEIER C,HEDERER B,GLAAB T,et al.Tiotropium versus salmeterol for the prevention of exacerbations of COPD[J].N Engl J Med,2011,364(12):1093-1103.
 DALAL A A,CANDRILLI S D,DAVIS K L.Outcomes and costs associated with initial maintenance therapy with fluticasone propionate-salmeterol xinafoate 250 microg/50 microg combination versus tiotropium in commercially insured patients with COPD[J]. Manag Care,2011,20(8):46-50,53-55.